Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm

Journal of Clinical Pharmacology

Volumn 55, Issue 3, 2015, Pages 251-257

  Li, Xi ^a   Liu, Rong ^a   Yan, Han ^a   Tang, Jie ^a   Yin, Ji Ye ^a   Mao, Xiao Yuan ^a   Yang, Fang ^b   Luo, Zhi Yin ^a   Tan, Sheng Lan ^c   He, Hui ^a   Chen, Xiao Ping ^a   Liu, Zhao Qian ^a   Li, Zhi ^a   Zhou, Hong Hao ^a   Zhang, Wei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

algorithms; epistasis; racial difference; single nucleotide polymorphism; warfarin

Indexed keywords

CYTOCHROME P450 2C9; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; VKORC1 PROTEIN, HUMAN;

ADULT; AGED; ALGORITHM; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG INDICATION; DRUG INTERACTION; GENE INTERACTION; GENOTYPE; HEART ATRIUM FLUTTER; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAJOR CLINICAL STUDY; RACE DIFFERENCE; TREATMENT DURATION; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MODEL; BLACK PERSON; BLOOD CLOTTING; CAUCASIAN; CHI SQUARE DISTRIBUTION; CHILD; COMPARATIVE STUDY; DOSE CALCULATION; DRUG EFFECTS; DRUG MONITORING; FEMALE; GENE FREQUENCY; GENETICS; MALE; METABOLISM; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; PROCEDURES; RISK FACTOR; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD COAGULATION; CHI-SQUARE DISTRIBUTION; CHILD; CYTOCHROME P-450 CYP2C9; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHARMACOGENETICS; PHENOTYPE; RISK FACTORS; VITAMIN K EPOXIDE REDUCTASES; WARFARIN; YOUNG ADULT;

EID: 84941653627     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.392     Document Type: Article

References (36)

1. Wells PS, Holbrook AM, Crowther NR, Hirsh J,. Interactions of warfarin with drugs and food. Ann Intern Med. 1994; 1 (9): 676-683.
2. Wysowski DK, Nourjah P, Swartz L,. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007; 9 (13): 1414-1419.
3. Takeuchi F, McGinnis R, Bourgeois S, et al., A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009; 5 (3): e1000433.
4. Wadelius M, Chen L, Eriksson N, et al., Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007; 121 (1): 23-34.
5. Rieder MJ, Reiner AP, Gage BF, et al., Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005; 352 (22): 2285-2293.
6. Wadelius M, Chen LY, Lindh JD, et al., The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009; 22 (4): 784-792.
7. Kamali F, Khan TI, King BP, et al., Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther. 2004; 75 (3): 204-212.
8. Biss TT, Avery PJ, Brandao LR, et al., VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood. 2012; 19 (3): 868-873.
9. Sconce EA, Khan TI, Wynne HA, et al., The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005; 1 (7): 2329-2333.
10. Klein TE, Altman RB, Eriksson N, et al., Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009; 360 (8): 753-764.
11. van Schie RM, Wessels JA, le Cessie, et al., Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J. 2011; 32 (15): 1909-1917.
12. Gage BF, Eby C, Johnson JA, et al., Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008; 84 (3): 326-331.
13. Anderson JL, Horne BD, Stevens SM, et al., Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007; 27 (2007): 2563-2570.
14. Tan SL, Li Z, Song GB, et al., Development and comparison of a new personalized warfarin stable dose prediction algorithm in Chinese patients undergoing heart valve replacement. Die Pharmazie. 2012; 67 (11): 930-937.
15. Zhu Y, Shennan M, Reynolds KK, et al., Estimation of warfarin maintenance dose based on VKORC1 (-1639 GA) and CYP2C9 genotypes. Clin Chem. 2007; 1 (2007): 1199-1205.
16. Cho HJ, On YK, Bang OY, et al., Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Clin Ther. 2011; 33 (10): 1371-1380.
17. Kim HS, Lee SS, et al., Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenet Genomics. 2009; 19 (2): 103-112.
18. Ohno M, Yamamoto A, Ono A, et al., Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur J Clin Pharmacol. 2009; 65 (11): 1097-1103.
19. Miao L, Yang J, Huang C, Shen Z,. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol. 2007; 63 (12): 1135-1141.
20. Huang SW, Chen HS, Wang XQ, et al., Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics. 2009; 19 (3): 226-234.
21. Wen MS, Lee M, Chen JJ, et al., Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther. 2008; 84 (1): 83-89.
22. Takahashi H, Wilkinson GR, Nutescu EA, et al., Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics. 2006; 16 (2): 101-110.
23. You JH, Wong RS, Waye MM, et al., Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. J Thromb Thrombolysis. 2011; 31 (1): 113-118.
24. Pirmohamed M, Burnside G, Eriksson N, et al., A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013; 12 (24): 2294-2303.
25. Kimmel SE, French B, Kasner SE, et al., A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013; 12 (24): 2283-2293.
26. Schalekamp T, Brasse BP, Roijers JF, et al., VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther. 2007; 81 (2): 185-193.
27. Van Schie RMF, Babajeff AMV, Schalekamp T, et al., An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. J Thromb Haemost. 2012; 10 (5): 767-772.
28. Schalekamp T, Brasse BP, Roijers JF, et al., VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther. 2006; 80 (1): 13-22.
29. Teichert M, van Schaik RH, Hofman A, et al., Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther. 2009; 85 (4): 379-386.
30. van Schie RM, Babajeff AM, Schalekamp T, et al., An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. J Thromb Haemost. 2012; 10 (5): 767-772.
31. Sayal KS, Duncan-McConnell DA, McConnell HW, Taylor DM,. Psychotropic interactions with warfarin. Acta Psychiatr Scand. 2000; 102 (4): 250-255.
32. Gage BF, Pharmacogenetics-based coumarin therapy. Hematology Am Soc Hematol Educ Program. 2006: 467-473.
33. Lindh JD, Holm L, Andersson ML, Rane A,. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009; 65 (4): 365-375.
34. Yamazaki H, Inoue K, Chiba K, et al., Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys-and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol. 1998; 56 (2): 243-251.
35. Rost S, Fregin A, Ivaskevicius V, et al., Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004; 5 (6974): 537-541.
36. Flockhart DA, O'Kane D, Williams MS, et al., Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008; 10 (2): 139-150.